What are the Historical Developments and Current Growth Metrics of the VariZIG Market?
The varizig market has seen considerable growth due to a variety of factors.
• Recently, the Varizig market size has seen a XX (HCAGR) growth. The expectations are that it will rise from a value of $XX million in 2024, to an increased value of $XX million in 2025, representing a compound annual growth rate (CAGR) of XX%.
The historical period's growth is largely credited to the increase in expenditure on healthcare, the rising occurrence of organ transplantation procedures, enhanced government funding for immunization programs, an increase in the elderly population, and an expansion in the scope of private insurance coverage.
What Is The Projected Growth Of The VariZIG Template Market?
The varizig market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the varizig market size is predicted to experience a CAGR of XX%, escalating to a value of $XX million by the year 2029.
This significant growth during the forecast period could be a result of the increasing rate of chickenpox incidents, escalating investments in the creation of varicella-related biologics, a heightened demand for immune globulin products, an increase in public health campaigns, and a surge in clinical trials. The forecast period is likely to experience major trends such as technological evolution, global humanitarian implementation, progress in recombinant DNA technology, the creation of innovative formulations, and the application of telemedicine.
What Are The Key Drivers Fueling Growth In The VariZIG Market?
The escalating rate of varicella-zoster virus infections is anticipated to stimulate the varizig market's progression. Varicella-zoster virus (VZV) is an incredibly infectious virus responsible for primary infections like chickenpox and can reoccur later to trigger shingles (herpes zoster). Factors such as decline vaccination rates, aging population, and immunosuppressive medical treatments have contributed to the rise in varicella-zoster virus (VZV) infections, resulting in conditions like chickenpox and shingles. Varizig plays a significant role in providing passive immunity to varicella-zoster virus patients, alleviating chickenpox symptoms' severity and duration, preventing potential complications in vulnerable individuals like those with a compromised immune system, and defending against severe outcomes in newborns and pregnant women exposed to the virus. For example, the Florida Department of Health, a US-based government agency, reported in November 2024 that the number of varicella cases had risen to 653 in 2023, a significant increase from the 428 cases in 2022. Consequently, the increasing prevalence of varicella-zoster virus infections propels the varizig market.
What Are The Principal Market Segments In The Global VariZIG Industry?
The varizig market covered in this report is segmented –
1) By Patient Condition: Immunocompromised Patients, Pregnant Women
2) By Distribution Channel: Hospitals, Pharmacies, Healthcare Providers
3) By End User: Adult, Geriatric, Pediatric
Pre-Book The VariZIG Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The VariZIG Market?
One prominent trend in the varizig market includes solidifying supply agreements for the product tailored towards high-risk patient groups, broadening distribution networks, and addressing the increasing need for passive immunization, especially in urgent and high-exposure situations. Supply agreements represent contracts that specify the elements and conditions for delivering goods or services, encompassing things like pricing, delivery timelines, and each party's responsibilities. For example, Kamada Ltd., a biopharmaceutical company based in Israel, declared a procurement agreement worth $11.4 million in July 2022 to provide its product VARIZIG to an unnamed international organization mainly active in Latin America. The supply operation is anticipated to be executed from Q4 2022 to H1 2023. This deal reflects Kamada's intent to accelerate its sales of FDA-certified plasma-derived therapies into international markets, emphasizing the business potential outside of North America. VARIZIG is specifically designed for post-exposure prophylaxis of varicella (chickenpox) in high-risk categories, such as immunocompromised patients and infants, thereby becoming a vital therapeutic choice for these demographics.
Who Are the Key Players In The VariZIG Market?
Major companies operating in the varizig market are:
• Emergent BioSolutions Inc.
What Are The Regional Insights Into The VariZIG Market?
North America was the largest region in the varizig market in 2024. The regions covered in the varizig market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
